# Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)

> **NCT04747522** · — · UNKNOWN · sponsor: **Oslo University Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Kidney Transplant Infection
- SARS-CoV Infection

## Interventions

- **DRUG:** SARS-CoV-2 vaccine

## Key facts

- **NCT ID:** NCT04747522
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-22
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04747522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04747522, "Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04747522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*